Biomarin Pharmaceutical Inc
Inside BioMarin’s Big Plans for 3Q16
BioMarin decided to withdraw its MAA (Marketing Authorization Application), given the expectation of a negative decision on the drug from the EMA.
BioMarin Has Suffered from Kyndrisa’s Rejection
The recent fall in BioMarin’s stock price is due to the rejection of its drug Kyndrisa, indicated for Duchenne muscular dystrophy.
Gauging Analysts’ Views on Tesaro Stock
In November, of the total 21 analysts covering Tesaro (TSRO) stock, 13 have given it “buy” or higher ratings, and eight have given it “hold” ratings.
What to Expect from BioMarin Pharmaceuticals in 2017
In 2016, BioMarin Pharmaceuticals (BMRN) reported revenues of around $1.1 billion, a ~25% increase year-over-year (or YoY).
What Spark Therapeutics’ Valuation Trend Indicates
Spark Therapeutics’ (ONCE) operating expenses decreased from $78.48 million in Q2 2017 to $59.78 million in Q2 2018.
How BioMarin Pharmaceutical Is Positioned Financially in August
In the second quarter, BioMarin Pharmaceutical (BMRN) reported revenues of $372.8 million compared to $317.4 million in Q2 2017.
XBI’s Large Caps: BioMarin Gives Update on Gene Therapy Study
The large-cap stocks of the SPDR S&P Biotech ETF (XBI) rose 0.3% on April 20, 2016. Large-cap stocks account for 19.3% of XBI’s portfolio.
What’s BioMarin’s Expected Revenue Growth in 2016 and 2017?
During its 2Q16 earnings call, BioMarin revised its 2016 revenue guidance. It now expects revenue to be $1.1 billion–$1.15 billion.
Europe Approved Biogen’s Elocta, Topped XBI’s Large-Cap Stocks
Biogen rose 1% on November 25. It closed at $292.30. It was trading 5.7% below the 100-day moving average price of $309.85. It passed the 20-day moving average.
Incyte Guidance on Jakafi Sends Stock High
On May 23, 2016, Incyte (INCY) was the biggest gainer among the large-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) with a gain of 3.9%.
BioMarin to Cross $1 Billion Revenue in 2016
BioMarin Pharmaceutical (BMRN) expects its existing commercialized drugs to add $1.1 billion and $1.2 billion to its top line in 2016.
How Does XBI Compare to Its 100-Day Moving Average?
The SPDR S&P Biotech ETF (XBI) rose marginally by 0.1% on April 20, 2016. Within XBI, Kite Pharma (KITE) closed at $48.98 on the day.
BioMarin: Why So Many ‘Buy’ Recommendations?
BioMarin (BMRN) is expected to report 2Q16 earnings on August 4, 2016. “Buy” ratings have increased to 94.7% from 90% on June 29, 2016.
Amgen Rises by 2% as XBI’s Large-Cap Stocks Rally
Amgen closed at $157.60 and was trading above its 50- and 100-day moving averages. The stock also witnessed a rise in trading volumes.
Alexion Continues to Rise on FDA’s Approval of Kanuma
Alexion Pharmaceuticals (ALXN) gained 2.5% on December 10, 2015. The stock went up after the FDA (Food and Drug Administration) approved its drug, Kanuma.
How Did Novo’s 2 Segments Perform in 1Q16?
Novo Nordisk’s two business segments are diabetes and obesity care and biopharmaceuticals. In 1Q16, they saw annual sales growth of 6% and 15%, respectively.
Revenue Drivers for Krystexxa, Horizon’s Orphan Biologic Drug
Horizon plans to drive Krystexxa through increased awareness and outreach, investing in its marketing and medical education as well as commercial infrastructure.
Overview of BioMarin: History and Product Portfolio
Here we present an overview of BioMarin. It’s based in California and was founded in 1997. It focuses on therapies for life-threatening rare genetic diseases.
Novartis Enters Agreement to Acquire AveXis
On April 9, 2018, Novartis AG announced that it had entered into an agreement to acquire AveXis for ~$8.7 billion.
BioMarin’s Disappointing 3Q16 Earnings
BioMarin Pharmaceutical (BMRN) reported its 3Q16 earnings on October 27, 2016. Revenues were $279.9 million, which was lower than Wall Street analysts’ projections.
Endo International Market Cap Fell: Reduced to Mid-Cap
Endo International (ENDP) announced its 4Q15 earnings on February 29, 2016. Its 4Q15 revenue was $1,074 million, and it reported a diluted earnings per share of $1.97.
Could Baxalta Maintain Its Leadership in the Hemophilia Space?
Baxalta’s (BXLT) hemophilia portfolio comprises of Advate, Adynovate, Rixubis, Recombinate, Hemofil M, Immunate, Immunine, and Prothromplex Total.
BioMarin Leads in the Market for Mucopolysaccharidoses Disorders
BioMarin holds three drugs in its portfolio indicated for different types of mucopolysaccharidoses disorders. They are Vimizim, Naglazyme, and Aldurazyme.
BMN 270: A Big Valuation Catalyst for BioMarin
On March 1, 2016, BioMarin received orphan drug designation for BMN 270 from the FDA. BioMarin’s stock jumped by about 6.96% the same day.
What to Expect from Shire’s Genetic Disease Franchise
Wall Street analysts expect Elaprase to earn $145.6 million in 2Q16 and $140.5 million in 3Q16.
BioMarin: How Much Revenue Growth in 2Q16?
According to analyst estimates, BioMarin should earn $278.4 million and $273.5 million in 2Q16 and 3Q16, respectively. That’s a yearly sales growth of 11.1% and 30.9%, respectively.
Why Roche Might Be Interested in BioMarin
With increased M&A activity in the pharmaceuticals and biotechnology space, it wouldn’t be surprising if Roche Holding (RHHBY) acquired BioMarin (BMRN).
Why Sesen Bio Stock Jumped Over 37% this Week
Sesen Bio (SESN), formerly known as Eleven Biotherapeutics, is developing next-generation antibody-drug conjugate therapies. The stock jumped ~26.1% to $2.27 yesterday.
Agios Outperformed: Rose 24.8% and Helped IBB Gain 3.2%
Agios Pharmaceuticals (AGIO) rose by a staggering 24.8% on October 27, 2015. It was the top performer in IBB’s portfolio.
How’s Alkermes Positioned Financially in September?
In the second quarter, Alkermes (ALKS) reported revenues of $304.6 million—compared to $218.8 million in the second quarter of 2017.
How Ionis’s Spinraza Performed in 3Q17
Ionis Pharmaceuticals’ Spinraza is a drug designed for the treatment of spinal muscular atrophy (or SMA), a type of severe motor-neuron disease.
How Did Jazz Pharmaceuticals Perform in the Second Quarter?
Jazz Pharmaceuticals reported revenues of $500.5 million in Q2 2018 compared to $394.4 million in Q2 2017, a ~27% YoY increase and a ~13% sequential increase.
Sangamo Therapeutics Rises on Positive Clinical Trial Results
On Friday last week, Sangamo Therapeutics (SGMO) and Pfizer (PFE) announced promising updated results from their Phase 1/2 ALTA trial.
Horizon Therapeutics or BioMarin: Which Is a Better Bet in July?
Horizon Therapeutics (HZNP) is up 23.13%, and BioMarin (BMRN) is down 6.62% year-to-date. Let’s study the drivers and risks for both these rare disease players in greater detail.
A Look at Sarepta Therapeutics’ Recent Developments
In the first nine months of 2018, Sarepta Therapeutics’ (SRPT) net income and EPS amounted to -$221.0 million and -$3.38, respectively, compared to -$26.7 million and -$0.47 in the same period the prior year.
How Is Sarepta Therapeutics Positioned in January?
In the first nine months of 2018, Sarepta Therapeutics’ net revenues grew ~123% YoY to reach $216.6 million from $97.3 million.
Sarepta Therapeutics Stock Rose 96% in 2018
On January 4, Sarepta Therapeutics (SRPT) stock closed at $115.43, which represents ~8.21% growth from its prior close.
Sage Therapeutics’ Operational Performance
In fiscal 2018 and fiscal 2019, Sage Therapeutics (SAGE) is expected to generate revenues of $79.41 million and $36.63 million, respectively.
Sage Therapeutics: Analyzing New Product Candidates
The Zulresso injection is Sage Therapeutics’ lead product candidate. The company has filed a new drug application.
Why Neurocrine Biosciences Stock Is Plummeting Today
Today, Neurocrine Biosciences (NBIX) is trading at $67.91, a ~20.83% fall from its closing price of $85.76 on December 11.
How BioMarin Pharmaceutical’s Financials Look in November
BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year.
Gauging Analysts’ Views on Clovis Stock
In November, of the 12 analysts covering Clovis Oncology (CLVS) stock, seven have given it “buy” or higher ratings, and five have given it “hold” ratings.
Allergan Beats EPS and Revenue Estimates: Q3 2018 Earnings
Allergan (AGN) released its Q3 2018 earnings today. The company beat Wall Street analysts’ estimates for EPS and revenues, and it reported non-GAAP EPS of $4.25 on revenues of $3.91 billion.
Allergan’s Q3 2018 Estimates: Revenue Decline Expected
Analysts are estimating that Allergan’s (AGN) third-quarter revenues will decline 3.8% to $3.88 billion.
Biogen: Analysts’ Recommendations on October 19
For Biogen, eight analysts recommended a “strong buy,” 12 recommended a “buy,” and nine recommended a “hold.”
Here Are the Key Products in Sage’s GABA Receptor Portfolio
Sage Therapeutics’ (SAGE) portfolio includes products under development for the treatment of life-threatening central nervous system (or CNS) disorders.
Estimates and Recommendations for Shire on September 19
Wall Street analysts expect Shire (SHPG) to report a 2.7% rise in revenue to ~$15.56 billion in 2018 compared to ~$15.16 billion in 2017.
Analysts Remain Bullish on BioMarin Pharmaceutical
Of the 23 analysts covering BioMarin Pharmaceutical (BMRN) in September, 19 of them have given the stock a “buy” or higher rating.
BioMarin Pharmaceutical and Its Promising Research Pipeline
Stocks focused on gene therapy have garnered strong investor interest in 2018. In this series, we’ll analyze four of those companies.
Estimates and Recommendations for Bluebird Bio on September 6
Wall Street analysts estimate that Bluebird Bio (BLUE) will report a 14.6% growth in revenues to ~$40.6 million in 2018 compared to $35.4 million in 2017.
Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy
Bluebird Bio (BLUE) released on September 5 its updated data from the Phase 2/3 Starbeam study evaluating investigational Lenti-D gene therapy.
How Analysts View BioMarin Pharmaceutical in August
On August 30, 2018, BioMarin Pharmaceutical (BMRN) stock closed at $99.26 which is 7% below its 52-week high of $106.20 on August 2.
Incyte’s Revenue Stream in Q2 2018
Incyte (INCY) reported revenue of $521.5 million in the second quarter, a 59.7% rise YoY (year-over-year).
Here’s What Tesaro’s Valuation Trend Indicates
Tesaro stock has been on a downward trajectory for the past 52 weeks. From a high of $135 on September 5, 2017, it has corrected to $27 in August.
Sarepta Therapeutics’ Q2 2018 Earnings and Revenue Growth
Sarepta Therapeutics (SRPT) released its Q2 2018 earnings on August 8, surpassing analysts’ estimates for EPS and revenues.
Wall Street Analysts Are Mostly Positive on Jazz Pharmaceuticals
Jazz Pharmaceuticals anticipates net revenues to be in the range of $1.88 million to $1.93 million in fiscal 2018.
How Ionis’s Q2 2018 Earnings Trended
Ionis reported 5% YoY growth in revenues to $117.7 million during Q2 2018 as compared to $112.3 million during the second quarter of 2017.
Bluebird Bio Misses Analysts’ Estimates in Q2 2018
Clinical-stage biotechnology company Bluebird Bio (BLUE) released its Q2 2018 results yesterday, missing analysts’ revenue and EPS estimates.
What Analysts Recommend for Bluebird Bio Stock
As previously discussed, analysts expect Bluebird Bio (BLUE) to post revenue of $9.6 million, a net adjusted loss of ~$123.5 million, and EPS of -$2.35 in the second quarter.
What to Expect from Shire’s Q2 2018 Earnings on July 31
Shire (SHPG) is set to release its Q2 2018 earnings on July 31. Wall Street analysts expect EPS of $3.67 on revenues of $3.8 billion.
Amgen Beats Estimates, Reports Growth in Q2 2018
Amgen (AMGN) reported in Q2 2018 results yesterday, surpassing analysts’ EPS and revenue estimates.
How Does BioMarin Pharmaceutical Look ahead of Its Q2 Earnings?
BioMarin Pharmaceutical (BMRN) plans to release its Q2 2018 results on August 2. In Q1 2018, BMRN reported net revenues of $373.4 million.
Sage Therapeutics’ GABA Receptor–Based Products
On June 12, Sage Therapeutics announced its expedited development plan for SAGE-217.
Vivus Stock Rose 60% Last Week
Vivus stock rose 60% between May 11 and May 18.
How Analysts View BioMarin Pharmaceuticals and Peers in April
Of the 23 analysts covering BioMarin Pharmaceuticals in April 2018, eight analysts gave the stock a “strong buy” rating.
Cash Flows and Valuation Metrics of BioMarin Pharmaceuticals
BioMarin Pharmaceuticals’ (BMRN) cash, cash equivalents, and investments increased from $1.3 billion in fiscal 2016 to $1.7 billion in fiscal 2017.
A Look at BioMarin Pharmaceuticals’ Therapy Portfolio
In December 2017, BioMarin Pharmaceuticals (BMRN) sold a rare pediatric disease priority review voucher to Novartis (NVS) for $125.0 million.
How Analysts View Tetraphase Pharmaceuticals in April 2018
Of eight analysts tracking Tetraphase Pharmaceuticals, one analyst rated it as a “strong buy,” and six analysts gave it a “buy” rating.
Analysts’ Ratings for Spark Therapeutics and Its Peers in April 2018
Of the 20 analysts covering Spark Therapeutics in April 2018, four have given the stock “strong buy” recommendations.
Analysts’ Recommendations for BioMarin Pharmaceutical
In March 2018, the EMA (European Medicines Agency) accepted BioMarin Pharmaceutical’s (BMRN) marketing authorization application for pegvaliase.
How BioMarin Pharmaceutical Performed in 4Q17 and 2017
In 4Q17, BioMarin Pharmaceutical (BMRN) generated revenue of $358.3 million, compared with $300.1 million in 4Q16.
Ionis Pharmaceuticals’ Valuation as of March 27, 2018
Wall Street analysts estimate that Ionis Pharmaceuticals (IONS) stock might increase 25.1% over the next 12 months.
Ionis Pharmaceuticals Stock as of March 27, 2018
Ionis Pharmaceuticals stock has fallen 6.9% over the last week. However, it rose 2.6% to close at $48.99 on March 26, 2018.
Key Updates on Akcea Therapeutics’ Volanesorsen
Ionis Pharmaceuticals’ (IONS) Volanesorsen is a drug for the treatment of familial chylomicronemia syndrome (or FCS) and familial partial lipodystrophy (or FPL).
A Look at Ionis’s Key Revenue Drivers in 4Q17
Ionis Pharmaceuticals (IONS) reported 7.5% growth in revenues to $172.3 million during 4Q17 as compared to revenues of $160.3 million during 4Q16.
How Did Ionis’s Revenues Trend in 4Q17?
Ionis (IONS) is a leading biopharmaceutical company focused on discovering, developing, and commercializing RNA-targeted therapies.
Alexion Pharmaceuticals in 4Q17 and Fiscal 2017
In 4Q17, Alexion Pharmaceuticals (ALXN) generated revenues of $910 million, which reflected ~10% growth on a YoY (year-over-year) basis.
How Biogen’s Spinraza Is Positioned for 2018
In 4Q17, Biogen’s (BIIB) Spinraza generated revenues of $363 million, which reflected 34% quarter-over-quarter growth.
A Look at Ionis’s 3Q17 Revenue Stream
Ionis Pharmaceuticals (IONS) reported a 9% rise in its revenue to $120.9 million in 3Q17 compared to $110.9 million in 3Q16.
How Was Incyte’s Revenue Stream in 3Q17?
Incyte’s total product royalty revenue was $44.5 million in 3Q17, a rise compared to $29.6 million in 3Q16.
Changes in Gilead’s Revenue Trends in 3Q17
Gilead’s revenue Gilead Sciences (GILD) reported revenue of $6.5 billion in 3Q17, a 13% fall from the revenue of $7.5 billion seen in 3Q16. The 3Q17 figure includes product revenue of $6.4 billion, and royalty, contract, and other revenue of $110 million. Analysts expect revenue to fall ~21.9% to $5.7 billion in 4Q17. Geographical sales The above […]
Analyst Recommendations for Alexion in December 2017
Twenty-one analysts are tracking Alexion Pharmaceuticals in December 2017. Six of them are recommending a “strong buy,” while 12 are recommending a “buy.”
Analyst Recommendations for Vertex Pharmaceuticals in October
After 3Q17, Vertex Pharmaceuticals (VRTX) increased its guidance for cystic fibrosis product revenues, from $1.87 billion–$2.1 billion to $2.10 billion–$2.15 billion.
Analysts’ Recommendations for Biogen in October 2017
Recent developments In October 2017, Biogen (BIIB) and Eisai expanded their existing agreement on the joint development and commercialization of Alzheimer’s disease therapies under investigation. According to the terms of the agreement, Eisai has the option to co-develop and co-commercialize Biogen’s aducanumab for the treatment of Alzheimer’s disease patients. The present expansion of the agreement […]
BioMarin’s Strong Pipeline Could Be a Long-Term Growth Driver
After success in the company’s phase 1/2 trial with BMN 270, an investigational gene therapy for hemophilia A, BioMarin Pharmaceuticals (BMRN) is expected to start phase 3 trials.
How Did BioMarin Pharmaceuticals’ Drugs Perform in 1H17?
In 2Q17, BioMarin Pharmaceuticals’ (BMRN) Aldurazyme generated revenues of around $20 million, which was a ~6% increase on a year-over-year (or YoY) basis.
How Is Jazz’s Defitelio Positioned after 2Q17?
In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Defitelio generated revenues of ~$30 million, which represents a ~10% fall YoY and a ~17% fall QoQ.
What Analysts Recommend for Acadia Pharmaceuticals in September
Of the nine analysts covering Acadia Pharmaceuticals in September 2017, two rated the stock a “strong buy,” six rated it a “buy,” and one rated it a “hold.”
This Part of Bioverativ’s Pipeline Could Be a Major Long-Term Growth Driver
In June 2017, the FDA accepted Bioverativ’s investigative new drug application for BIVV001, a drug designed to treat prophylaxis from bleeding associated with hemophilia A.
Behind Bioverativ’s Analyst Recommendations This September
Of the 12 analysts tracking Bioverativ (BIVV), three recommend a “strong buy” for the stock, while one recommends a “buy,” and seven recommend a “hold.”
How Are Orkambi and Kalydeco Positioned after 2Q17?
In 2Q17, Vertex Pharmaceuticals’ (VRTX) Orkambi generated revenues of around $324 million, which reflected a whopping ~32% growth on a year-over-year (or YoY) basis and ~10% growth on a quarter-over-quarter basis.
Understanding Incyte’s 2Q17 Revenue Stream
Incyte’s 2Q17 revenue growth was driven by the increased demand for Jakafi.
What Drove Biogen Stock in 2Q17?
Biogen (BIIB) stock has risen ~0.40% in 2Q17 and ~4.1% year-to-date as of July 7, 2017.
The Rise of Amgen Stock in 2Q17
Amgen (AMGN) stock has risen ~5.8% in 2Q17, while it has risen ~17.4% year-to-date as of July 7, 2017.
What Analysts Recommend for BioMarin Pharmaceuticals
A total of 20 analysts were analyzing BioMarin Pharmaceuticals in July 2017. Six analysts recommended a “strong buy,” while nine analysts suggested a “buy.”
BioMarin Expects These Drugs to Generate Steady Revenues
In 2016, BioMarin Pharmaceuticals’ (BMRN) Naglazyme generated revenues of around $297 million, a ~2% year-over-year (or YoY) decline.
Kuvan Could Boost BioMarin’s Revenue Growth in 2017
In 2016, BioMarin Pharmaceuticals’ (BMRN) Kuvan reported revenues of around $348 million, a ~45% year-over-year (or YoY) increase.
Developments for Ionis Pharmaceuticals after 1Q17
Ionis’s recent developments As discussed earlier, Ionis Pharmaceuticals (IONS) is focused on the development of drugs for the treatment of diseases with limited or no therapeutic options. Corporate developments In April 2017, Ionis entered into a collaborative agreement with Suzhou Ribo Life Science for the development and commercialization of RNA[1.ribonucleic acid]-targeted therapeutics in China. In […]
Analysts’ Views on Alexion Pharmaceuticals and Its Peers
Of the 21 analysts analyzing Alexion Pharmaceuticals, six analysts recommended a “strong buy” and 11 analysts recommended a “buy.”
Strensiq: Key Growth Driver for Alexion Pharmaceuticals in 2017
In 1Q17, Alexion Pharmaceuticals’ (ALXN) Strensiq generated revenue of ~$74 million, which reflects ~4% quarter-over-quarter and ~124% YoY growth.